Critical Comparison: SQI Diagnostics (OTCMKTS:SQIDF) and Bruker (NASDAQ:BRKR)

SQI Diagnostics (OTCMKTS:SQIDF) and Bruker (NASDAQ:BRKR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for SQI Diagnostics and Bruker, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SQI Diagnostics	0	0	0	0	0.00
Bruker	2	4	6	2	2.57

Bruker has a consensus target price of $56.64, suggesting a potential downside of 1.83%. Given Bruker’s stronger consensus rating and higher probable upside, analysts clearly believe Bruker is more favorable than SQI Diagnostics.

Insider & Institutional Ownership

79.5% of Bruker shares are held by institutional investors. 27.2% of Bruker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares SQI Diagnostics and Bruker’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SQI Diagnostics	N/A	N/A	N/A
Bruker	-2.35%	12.47%	4.91%

Earnings and Valuation

This table compares SQI Diagnostics and Bruker”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQI Diagnostics	N/A	N/A	N/A	N/A	N/A
Bruker	$3.44 billion	2.56	-$8.60 million	($0.70)	-82.43

SQI Diagnostics has higher earnings, but lower revenue than Bruker.

Summary

Bruker beats SQI Diagnostics on 9 of the 10 factors compared between the two stocks.

About SQI Diagnostics

SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company also offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung; and a COVID-19 at-home antibody test kit; the RALI-Dx, a COVID-19 severity triage lab test; and RALI-fast, a COVID-19 severity triage POC test. In addition, it offers microarray tests for protein and antibody testing workflow. The company was founded in 1999 and is headquartered in Toronto, Canada.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.